110 related articles for article (PubMed ID: 2531855)
1. Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line.
Romano JW; Ehrhart JC; Duthu A; Kim CM; Appella E; May P
Oncogene; 1989 Dec; 4(12):1483-8. PubMed ID: 2531855
[TBL] [Abstract][Full Text] [Related]
2. Specific interaction between a subset of the p53 protein family and heat shock proteins hsp72/hsc73 in a human osteosarcoma cell line.
Ehrhart JC; Duthu A; Ullrich S; Appella E; May P
Oncogene; 1988 Nov; 3(5):595-603. PubMed ID: 2978869
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of genes whose expressions are altered in rat 6 fibroblasts transformed by mutant p53(val135).
Yam JW; Zheng JY; Hsiao WL
Biochem Biophys Res Commun; 1999 Dec; 266(2):472-80. PubMed ID: 10600527
[TBL] [Abstract][Full Text] [Related]
4. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bartek J; Iggo R; Gannon J; Lane DP
Oncogene; 1990 Jun; 5(6):893-9. PubMed ID: 1694291
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
Hinds PW; Finlay CA; Quartin RS; Baker SJ; Fearon ER; Vogelstein B; Levine AJ
Cell Growth Differ; 1990 Dec; 1(12):571-80. PubMed ID: 2288874
[TBL] [Abstract][Full Text] [Related]
6. Partial transformation of human tumor cell lines showing defective interaction between unusual p53 gene product and SV40 large-T antigen.
Van Roy F; Liebaut G; Mareel M; Fiers W
Oncogene; 1990 Feb; 5(2):207-18. PubMed ID: 2157184
[TBL] [Abstract][Full Text] [Related]
7. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.
Takahashi T; D'Amico D; Chiba I; Buchhagen DL; Minna JD
J Clin Invest; 1990 Jul; 86(1):363-9. PubMed ID: 2164047
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the p53 gene occur in diverse human tumour types.
Nigro JM; Baker SJ; Preisinger AC; Jessup JM; Hostetter R; Cleary K; Bigner SH; Davidson N; Baylin S; Devilee P
Nature; 1989 Dec; 342(6250):705-8. PubMed ID: 2531845
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor genes.
Levine AJ
Bioessays; 1990 Feb; 12(2):60-6. PubMed ID: 2140509
[TBL] [Abstract][Full Text] [Related]
10. The properties of p53 proteins selected for the loss of suppression of transformation.
Olson DC; Levine AJ
Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
[TBL] [Abstract][Full Text] [Related]
11. Cloning of the p53-dependent origin of cellular DNA replication.
Iguchi-Ariga SM; Okazaki T; Itani T; Ariga H
Oncogene; 1988 Nov; 3(5):509-15. PubMed ID: 2978868
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines.
Davidoff AM; Pence JC; Shorter NA; Iglehart JD; Marks JR
Oncogene; 1992 Jan; 7(1):127-33. PubMed ID: 1741160
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells.
Stürzbecher HW; Chumakov P; Welch WJ; Jenkins JR
Oncogene; 1987 May; 1(2):201-11. PubMed ID: 2830579
[TBL] [Abstract][Full Text] [Related]
15. Selective loss of endogenous p21waf1/cip1 induction underlies the G1 checkpoint defect of monomeric p53 proteins.
Tarunina M; Grimaldi M; Ruaro E; Pavlenko M; Schneider C; Jenkins JR
Oncogene; 1996 Aug; 13(3):589-98. PubMed ID: 8760300
[TBL] [Abstract][Full Text] [Related]
16. p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis.
Stürzbecher HW; Maimets T; Chumakov P; Brain R; Addison C; Simanis V; Rudge K; Philp R; Grimaldi M; Court W
Oncogene; 1990 Jun; 5(6):795-81. PubMed ID: 2141683
[TBL] [Abstract][Full Text] [Related]
17. Wild type human p53 is antiproliferative in SV40-transformed hamster cells.
Mercer WE; Amin M; Sauve GJ; Appella E; Ullrich SJ; Romano JW
Oncogene; 1990 Jul; 5(7):973-80. PubMed ID: 2165234
[TBL] [Abstract][Full Text] [Related]
18. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
19. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
20. Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.
Srivastava S; Wang S; Tong YA; Hao ZM; Chang EH
Cancer Res; 1993 Oct; 53(19):4452-5. PubMed ID: 8402611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
